Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study

3/18 Late treatment study

Cai et al., Engineering, doi:10.1016/j.eng.2020.03.007 (Peer Reviewed)
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study

Source PDF Share Tweet

Comparison of 35 FPV patients and 35 LPV/RTV patients, showing significant improvements in chest CT and faster viral clearance with FPV.

Cai et al., 3/18/2020, retrospective, China, Asia, peer-reviewed, 26 authors.

risk of no improvement in CT, 68.7% lower, RR 0.31, p = 0.04, treatment 35, control 45, multivariate.

risk of no virological cure, 70.9% lower, RR 0.29, p = 0.03, treatment 35, control 45, multivariate.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.

All 18 studies All Outcomes

Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.

Submit